ArriVent Biopharma

arrivent.com

ArriVent Biopharma is a clinical-stage biopharmaceutical company founded in 2021, focused on developing and commercializing differentiated medicines for difficult-to-treat diseases, particularly cancer. The company aims to leverage innovative therapies from global markets, ensuring they reach patients worldwide. With a strong emphasis on oncology, ArriVent utilizes its team's extensive drug development experience to advance its lead candidate, firmonertinib, and a pipeline of novel oncology therapeutics. Their selective in-licensing strategy and partnerships enable them to identify high-quality drug candidates, maximizing their potential for regulatory approval and commercial success.